# Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct06252675/  
OnCo record `nct06252675` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Obinutuzumab, Glofitamab, Pirtobrutinib and clonoSEQ in Mantle cell lymphoma, run by University of California, San Francisco, now recruiting.

## Summary

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT06252675 by University of California, San Francisco, with 30 participants planned, started 2024-06-11 and due to reach its primary completion in 2028-07-31. Interventions recorded: Obinutuzumab, Glofitamab, Pirtobrutinib, Tumor Imaging, Biospecimen Collection, ClonoSeq Assay, Bone Marrow Biopsy. Conditions recorded: Mantle Cell Lymphoma.

Linked to the drug clonoSEQ because the registry names it among its interventions and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06252675
- Phase: 2
- Setting: A Multicenter Phase 2 Study of Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- Sponsor: University of California, San Francisco
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06252675: https://clinicaltrials.gov/study/NCT06252675

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [clonoSEQ](https://onco.cc/drugs/clonoseq/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct06252675.json